美国 · 股市与财经 · Morningstar
'Pharma Bro' Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks
The Federal Trade Commission and seven states say Shkreli should be held in contempt Martin Shkreli was found guilty in 2017 of two counts of securities fraud and one count of…
在 Morningstar 阅读全文 登录后可收藏MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.morningstar.com)
